Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04197453 · ClinicalTrials.gov registry record
The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)
A clinical trial, sponsored by Amgen.
- Terminated
- Registry status
- 752
- Enrollment target
NCT04197453: Clinical Trial study, sponsored by Amgen.
NCT04197453 is a clinical trial that was terminated before completion, run by Amgen. The registered enrollment target is 752 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04197453 was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- 752 participants
- Enrollment target
Study Summary
cvMOBIUS is a North American registry of patients with ASCVD aimed at understanding patterns of care in ASCVD while evaluating the real world effectiveness of PCSK9 inhibitors.
Primary Outcome
Number of incident all-cause deaths, non-fatal MI, and non-fatal IS events (whichever occurs first) divided by the person-time at risk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2020-12-21 |
Why NCT04197453 stopped before completion
NCT04197453 is an observational study that tracks outcomes without assigning an intervention. The registered 752 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04197453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04197453 about?
NCT04197453 is a clinical study titled "The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)". cvMOBIUS is a North American registry of patients with ASCVD aimed at understanding patterns of care in ASCVD while evaluating the real world effectiveness of PCSK9 inhibitors.
What is the current status of trial NCT04197453?
This trial is currently terminated. The enrollment target is 752 participants. The study started on 2019-12-06. Estimated completion is 2020-12-21.
Who is sponsoring clinical trial NCT04197453?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06559306 · 752 participants · Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI